Withings ECG-Monitor Study

Not Applicable

Completed

• Conditions: Atrial Fibrillation
• Interventions: Device: Electrocardiogram recording

• Registration Number: NCT05316337
• Lead Sponsor: Withings

Brief Summary

The aim of the study is to evaluate the performance of Withings WBS08 with embedded Withings ECG Monitor in the automatic detection of atrial fibrillation

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-03-18
• Study First Submitted QC: 2022-03-30
• Study First Posted: 2022-04-07
• Study Start: 2022-07-15
• Primary Completion: 2023-09-01
• Study Completion: 2023-09-01
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-18
• Last Update Posted: 2024-03-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 650

Inclusion Criteria

• Male or female who are 22 years of age or older,
• Subject able to read, understand, and provide written informed consent,
• Subject willing and able to participate in the study procedures as described in the consent form,
• Subject able to communicate effectively with and willing to follow instructions from the study staff.

Exclusion Criteria

• Vulnerable subject with regard to regulations in force

  • Subject who is deprived of liberty by judicial, medical or administrative decision,
  • Underage subject,
  • Legally protected subject, or subject who is unable, linguistic or psychic incapacity, to sign the written informed consent form.
  • Subject within several of the above categories,

• Subject who refused to participate in the study,

• Subject mentally impaired resulting in limited ability to cooperate

• Subject with electrical stimulation by pacemaker

• Patient with pathologic disorder that may affect motricity resulting in significant tremor that prevents subject from being able to hold still (e.g Parkinson disease)

• Patient unable to stay in an upright position for the duration of study measures

• Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, may increase the risk to the subject or renders data uninterpretable (e.g., recent or ongoing unstable angina, decompensated heart failure, active myocarditis or pericarditis)

• Acute pulmonary embolism or pulmonary infarction, within 90 days of screening

• Stroke or transient ischemic attack within 90 days of screening

• Active life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block).

• History of life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block)

• Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis over electrode attachment sites

• Known sensitivity to medical adhesives, isopropyl alcohol, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands

• Weight more than 180 kg

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Normal Sinus Rhythm	Electrocardiogram recording	-
Atrial fibrillation	Electrocardiogram recording	-

Primary Outcome Measures

Name	Time	Method
Co-primary outcomes	4 months	Specificity (percentage of true negatives) in detecting AF from conclusive recordings generated by the software under test, that is recordings resulting in a classification of AF or SR by the SUT, compared to the reference 12-lead ECG.

Secondary Outcome Measures

Name	Time	Method
Evaluation of the classification into heart rate subgroups	4 months	The classification into heart rate subgroups will be evaluated for the pairs of strips such that the rhythm classification of the 12-lead ECG is either SR or AF and such that the strip generated by the SUT is classified as either SR or AF. The evaluation will be assessed with the concordance of classifications, i.e. the percentage P of identical classifications by the SUT and the reference method, into each of the four following subgroups: * SR with a HR between 50 and 99 bpm; * SR with a HR between 100 and 150 bpm; * AF with a HR between 50 and 99 bpm; * AF with a HR between 100 and 150 bpm
Heart Rate equivalence	4 months	heart rate will be determined by independent cardiologists, or cardiac technicians supervised by cardiologists, from each six-channel strip recorded with the SUT and from each lead I, II, III, aVR, aVL, aVF of the 12-lead reference ECG
Clinical Equivalence of ECG waveforms	4 months	The durations of the QT intervals, QRS complex widths, and PR intervals will be measured by cardiologists with a caliper and according to a set of predetermined rules for each of the 6 leads of the strips generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG.

Trial Locations

Locations (10)

Florida Cardiovascular Research; 🇺🇸 Hialeah, Florida, United States

The Angel Medical Research; 🇺🇸 Miami Lakes, Florida, United States

FWD Clinical Research; 🇺🇸 Boca Raton, Florida, United States

American Institute of Therapeutics; 🇺🇸 Lake Bluff, Illinois, United States

Cambridge Medical Trials; 🇺🇸 Alexandria, Louisiana, United States

Texas Heart Institute; 🇺🇸 Houston, Texas, United States

Heartbeat Health; 🇺🇸 New York, New York, United States

LINQ Research LLC; 🇺🇸 Pearland, Texas, United States

Henri-Mondor Hospital; 🇫🇷 Créteil, Île De France, France

Diverse Clinical Research; 🇺🇸 Miami, Florida, United States